Molecular Profiling Strategy Nets Cleave $42M in Series A Funding

Founded only a year ago, cancer drug firm Cleave Biosciences attracted a whopping $42 million in a Series A financing, expected to be disclosed Tuesday, to push its lead programs into the clinic.

Founded only a year ago, cancer drug firm Cleave Biosciences attracted a whopping $42 million in a Series A financing, expected to be disclosed Tuesday, to push its lead programs into the clinic.